ORCL, RACE, DAL, ALB and more
Check out the companies making the biggest moves in midday trading: Oracle — Shares of the software company rose more than 3% on Thursday after Baird initiated coverage with a outperform rating and a $365 price taget. The firm said Oracle has a strong position in the artificial intelligence growth story. The stock has had a wild ride in recent sessions as investors debated its outlook. Week to date, shares have gained 4%. MP Materials — Shares of the rare earth materials producer rose 7%. BMO Capital Markets reinstated coverage at a market perform rating, calling MP the U.S.’ “rare earth champion” following a partnership with the Department of Defense. Meanwhile, China said it tightened rare earth export controls ahead of a potential meeting between President Donald Trump and Chinese leader Xi Jinping. Albemarle , Lithium Americas — Shares of lithium producers also rose as China looks to require export licenses for some types of lithium ion batteries. Albemarle gained 7%, while Lithium Americas added about 3%. Tilray Brands — Shares of the cannabis company rose about 24% after reporting a fiscal first-quarter profit on the back of stronger-than-expected profit. Ferrari — The luxury carmaker tumbled 14% after it trimmed its electrification targets . Ferrari said it expects its 2030 sports car model line-up to be made up of 40% internal combustion engine cars, 40% hybrid and 20% fully electric vehicles. That’s down from its prior target of 40% EV sales by the end of the decade. Delta Air Lines — Shares rose nearly 5% after the company issued strong guidance and posted third-quarter results that beat analyst expectations. The airline earned an adjusted $1.71 per share on revenue of $15.2 billion. Analysts expected by LSEG expected a profit of $1.53 per share on revenue of $15.06 billion. Rival United Airlines also added 3%, in the wake of Delta’s report. Akero Therapeutics — The biopharma company rallied nearly 17% after it announced it would be acquired by Novo Nordisk for $54 per share, or $4.7 billion, in cash. Akero makes drugs aimed at treating metabolic dysfunction-associated steatohepatitis, or MASH. Its efruxifermin drug, EFX, is in phase 3 trials. Novo Nordisk shares fell more than 1%. PepsiCo — The snacks and beverage giant climbed about 3% after reporting third-quarter results that beat analyst expectations. The company earned an adjusted $2.29 per share on revenue of $23.94 billion. Analysts expected a profit of $2.26 per share on revenue of $23.83 billion, according to LSEG. Oklo — Shares gained nearly 3% after Canaccord Genuity initiated coverage of the nuclear technology company with a Buy rating. The firm anticipates strong long-term demand for nuclear energy, with Oklo emerging as a leader. Azz — The stock dropped more than 3% after the provider of hot-dip galvanizing and coil coating solutions posted fiscal second-quarter earnings and revenue that missed expectations. Azz said it saw weaker demand in several end markets. —CNBC’s Michelle Fox, Fred Imbert, Alex Harring, Sarah Min and Liz Napolitano contributed reporting (Learn the best 2026 strategies from inside the NYSE with Josh Brown and others at CNBC PRO Live. Tickets and info here .)
Post Comment